Headache

GoExceed Accelerates the Value of Data in Latest Release of Solve(X)

Retrieved on: 
Tuesday, April 9, 2024
Mobile, Wireless, Technology, Professional Services, Software, Small Business, Data Analytics, Data Management, Supply Chain Management, Retail, Artificial Intelligence, Data science, Headache, Organization, Data management, Chvátal

GoExceed, a market leader in data management automation software, today unveils the latest iteration of Solve(X)—a cutting-edge platform for automated data and asset management.

Key Points: 
  • GoExceed, a market leader in data management automation software, today unveils the latest iteration of Solve(X)—a cutting-edge platform for automated data and asset management.
  • This release introduces new features that enhance efficiency and maximize the value of mobile spending.
  • The platform’s latest release provides comprehensive tools for managing mobile devices and plans and offers a holistic view of over 1 million cellular connections.
  • “With this latest release of Solve(X) we have expanded the value we deliver clients, providing a cost optimization solution that delivers meaningful efficiency gains,” continued Chvatal.

Cleveland Guardians Gain Competitive Advantage by Selecting Windstream to Modernize its Network Services

Retrieved on: 
Tuesday, April 9, 2024
Sports, Data Management, Technology, Professional Services, Security, Telecommunications, Data Analytics, Software, Artificial Intelligence, Networks, Baseball, Cloud, Organization, Headache, Sport, Environment, Cleveland Guardians, Connect, Radio, MLB, Guardian, Google Cloud Platform, Major League Baseball, Video game

Windstream Enterprise (WE), a leading IT managed services provider, has been selected by the Major League Baseball (MLB) franchise Cleveland Guardians for its managed software-defined wide-area network (SD-WAN) services to achieve a dedicated and simplified cloud network connection.

Key Points: 
  • Windstream Enterprise (WE), a leading IT managed services provider, has been selected by the Major League Baseball (MLB) franchise Cleveland Guardians for its managed software-defined wide-area network (SD-WAN) services to achieve a dedicated and simplified cloud network connection.
  • Guardians’ front office staff, coaches, scouts and players are dispersed among eight locations, including Progressive Field and their affiliated minor league team stadiums.
  • Under their previous network, limited bandwidth was disrupting the team’s ability to disseminate real-time information such as players’ statistics, team performance metrics and videos.
  • “The Guardians are hitting a home run with Windstream solutions, and we’re thrilled about this new partnership.”
    To learn more about cloud-optimized connectivity solutions from Windstream, please visit windstreamenterprise.com .

Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

Retrieved on: 
Sunday, April 7, 2024
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical Trials, Arrowhead, Principal, Urinary tract infection, JAMA Cardiology, Apolipoprotein C-III, Risk, Headache, Patient, Hypertriglyceridemia, Diarrhea, COVID-19, American College, APOC3, Pancreatitis, Safety, Pharmaceutical industry

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly ARO-APOC3) in patients with severe hypertriglyceridemia (SHTG).

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented final data from the double-blind treatment period of its Phase 2 SHASTA-2 study of investigational plozasiran (formerly ARO-APOC3) in patients with severe hypertriglyceridemia (SHTG).
  • Results from the SHASTA-2 study showed dramatic, consistent, and sustained reductions in Apolipoprotein C-III (APOC3) and triglycerides and improvement in multiple atherogenic lipoprotein levels.
  • These data were presented in a late-breaking oral presentation today at the American College of Cardiology 73rd Annual Scientific Session & Expo (ACC.24) in Atlanta and simultaneously published in the journal JAMA Cardiology .
  • Subjects treated with plozasiran also showed improvements in multiple atherogenic lipid and lipoprotein levels, including remnant cholesterol, HDL-cholesterol, and non-HDL cholesterol.

Mesh Payments Simplifies Guest Travel for Candidates and Contractors with Key Advancements to Its Travel Management Solution

Retrieved on: 
Tuesday, April 9, 2024
Accounting, HR, Travel, Headache, Policy, Chloride, Communication, Mesh, Hotel

NEW YORK, April 9, 2024 /PRNewswire/ -- Mesh Payments , the innovator in global travel and expense management, today announced a new guest travel solution that eliminates the manual and cumbersome process traditionally associated with the booking and reimbursement of candidate and guest travel.

Key Points: 
  • NEW YORK, April 9, 2024 /PRNewswire/ -- Mesh Payments , the innovator in global travel and expense management, today announced a new guest travel solution that eliminates the manual and cumbersome process traditionally associated with the booking and reimbursement of candidate and guest travel.
  • Guest travel is the latest innovation to the Mesh Travel & Expense Management platform, which provides unprecedented efficiency and spend visibility while meeting the rigorous compliance standards of global, multi-entity corporations.
  • Guest travel streamlines travel booking and expenses for contractors, candidates and other guests, allowing them to book their own itineraries and eliminate expense reimbursements.
  • "This is just the beginning of our journey to streamline travel and expense management for companies worldwide."

Caffeine Powder Market to Reach $1,612.1 Million, Globally, by 2032 at 5.5% CAGR: Allied Market Research

Retrieved on: 
Monday, April 8, 2024
Alertness, Health, Fatigue, Headache, Growth, Data, Drink, Migraine, Caffeine, Medicinal plants

WILMINGTON, Del., April 8, 2024 /PRNewswire/ -- Allied Market Research published a report, titled, "Caffeine Powder Market by Source (Synthetic Caffeine, Natural Caffeine), and Application (Food and Beverages, Pharmaceuticals, Cosmetics and Personal Care, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032". According to the report, the "caffeine powder market" was valued at $949.4 million in 2022, and is estimated to reach $1,612.1 million by 2032, growing at a CAGR of 5.5% from 2023 to 2032.

Key Points: 
  • Moreover, caffeine powder offers consumers the flexibility to customize their caffeine intake according to their preferences and needs.
  • In addition, the globalization of the caffeine powder market has led to increased accessibility and availability of products across regions and channels.
  • Furthermore, Europe is home to several prominent pharmaceutical and food industries that utilize caffeine powder in various formulations, further bolstering market growth.
  • With its robust market infrastructure, consumer demand, and regulatory framework, Europe is expected to maintain its leadership position in the global caffeine powder market.

Caffeine Powder Market to Reach $1,612.1 Million, Globally, by 2032 at 5.5% CAGR: Allied Market Research

Retrieved on: 
Monday, April 8, 2024
Alertness, Health, Fatigue, Headache, Growth, Data, Drink, Migraine, Caffeine, Medicinal plants

WILMINGTON, Del., April 8, 2024 /PRNewswire/ -- Allied Market Research published a report, titled, "Caffeine Powder Market by Source (Synthetic Caffeine, Natural Caffeine), and Application (Food and Beverages, Pharmaceuticals, Cosmetics and Personal Care, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032". According to the report, the "caffeine powder market" was valued at $949.4 million in 2022, and is estimated to reach $1,612.1 million by 2032, growing at a CAGR of 5.5% from 2023 to 2032.

Key Points: 
  • Moreover, caffeine powder offers consumers the flexibility to customize their caffeine intake according to their preferences and needs.
  • In addition, the globalization of the caffeine powder market has led to increased accessibility and availability of products across regions and channels.
  • Furthermore, Europe is home to several prominent pharmaceutical and food industries that utilize caffeine powder in various formulations, further bolstering market growth.
  • With its robust market infrastructure, consumer demand, and regulatory framework, Europe is expected to maintain its leadership position in the global caffeine powder market.

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024
Diabetes, Anaphylaxis, IgA nephropathy, Glaucoma, CYP3A4, Dermatitis, Patient, Parasitism, Indinavir, Budesonide, Ritonavir, Quality of life, Peripheral edema, UPCR, Drug interaction, Vaccine, Saquinavir, Erythromycin, Congress, White, Risk, Headache, Spasm, Ketoconazole, Immunoglobulin A, Liver, Adrenal insufficiency, Immune system, Prediabetes, Proteinuria, Hypertension, Contraindication, Arthralgia, Ciclosporin, International Society, Immunosuppression, KOL, Acne, Infection, EGFR, Measles, Miscarriage, ISN, Hypersensitivity, Pregnancy, HPA, Chickenpox, Fetus, Birth, Itraconazole, CALT, Upper respiratory tract infection, Osteoporosis, Kidney, Cataract, Tropical ulcer, Pharmaceutical industry

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024
Diabetes, Anaphylaxis, IgA nephropathy, Glaucoma, CYP3A4, Dermatitis, Patient, Parasitism, Indinavir, Budesonide, Ritonavir, Quality of life, Peripheral edema, UPCR, Drug interaction, Vaccine, Saquinavir, Erythromycin, Congress, White, Risk, Headache, Spasm, Ketoconazole, Immunoglobulin A, Liver, Adrenal insufficiency, Immune system, Prediabetes, Proteinuria, Hypertension, Contraindication, Arthralgia, Ciclosporin, International Society, Immunosuppression, KOL, Acne, Infection, EGFR, Measles, Miscarriage, ISN, Hypersensitivity, Pregnancy, HPA, Chickenpox, Fetus, Birth, Itraconazole, CALT, Upper respiratory tract infection, Osteoporosis, Kidney, Cataract, Tropical ulcer, Pharmaceutical industry

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy

Retrieved on: 
Saturday, April 6, 2024
Guillain–Barré syndrome, Bone marrow, Medical College of Wisconsin, Encephalopathy, Survival, Immunotherapy, BCMA, Patient, Hypotension, Mortality, B-cell maturation antigen, Edema, Periodic breathing, Associate professor, Dexamethasone, Certification, Neutropenia, Dizziness, Risk, Headache, Chills, Myelodysplastic syndrome, Coagulopathy, DPD, Johnson & Johnson, Immune system, Effect, Fatigue, Thrombocytopenia, Food, Disease, Drive, Appetite, Lymphocytopenia, JNJ, Constipation, Multiple myeloma, Acute myeloid leukemia, CRS, Death, Hypersensitivity, Cytopenia, Cytokine release syndrome, ASCO, Use, Hematology, FDA, PVD, Annual general meeting, T cell, DSM-IV codes, Incidence, Tachycardia, Bortezomib, Diarrhea, Viral, Hope, United, Cough, Daratumumab, Nausea, Society, Division, Physician, Pharmaceutical industry

HORSHAM, Pa., April 5, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.1 With this approval, CARVYKTI® becomes the first and only B-cell maturation antigen (BCMA)-targeted therapy approved for the treatment of patients with multiple myeloma as early as first relapse.

Key Points: 
  • "This milestone underscores our commitment to improve outcomes for patients and transform the treatment of multiple myeloma with CARVYKTI," said Jordan Schecter, M.D., Vice President, Disease Area Leader, Multiple Myeloma, Johnson & Johnson Innovative Medicine.
  • CARVYKTI® is a cell therapy that works by harnessing a patient's immune system, or T cells, to fight the disease.
  • Treatment requires extensive training, preparation, and certification to ensure a positive experience for patients.
  • Since initial approval in February 2022, Johnson & Johnson has made significant advances in manufacturing to rapidly scale CARVYKTI® production.

BAM Capital Reviews: Elevating Real Estate Investments for Accredited Investors

Retrieved on: 
Friday, April 5, 2024
Acquisition, Headache, Sale, Heart, Safety, Commercial property

INDIANAPOLIS, April 5, 2024 /PRNewswire/ -- In the competitive arena of real estate investment, BAM Capital stands out as a beacon of excellence, offering accredited investors unparalleled access to multifamily syndication opportunities.

Key Points: 
  • INDIANAPOLIS, April 5, 2024 /PRNewswire/ -- In the competitive arena of real estate investment, BAM Capital stands out as a beacon of excellence, offering accredited investors unparalleled access to multifamily syndication opportunities.
  • With a rich portfolio boasting impressive returns and a steadfast commitment to investor satisfaction, BAM Capital is redefining the landscape of real estate investment.
  • For accredited investors seeking to diversify their portfolios with real estate, BAM Capital presents a compelling option.
  • BAM Capital is the private equity arm of The BAM Companies, specializing in the acquisition and management of multifamily apartment communities.